Have a feature idea you'd love to see implemented?
Let us know!
IKT Inhibikase Therapeutics Inc
Price (delayed)
$3.07
Market cap
$206.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.68
Enterprise value
$205.58M
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional
Highlights
The company's debt fell by 39% QoQ and by 20% YoY
The EPS has grown by 27% YoY and by 3.6% from the previous quarter
The equity has dropped by 110% since the previous quarter and by 104% year-on-year
Inhibikase Therapeutics's gross profit has plunged by 100% YoY and by 100% from the previous quarter
Key stats
What are the main financial stats of IKT
Market
Valuations
Earnings
Shares outstanding
67.19M
Market cap
$206.28M
Enterprise value
$205.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
27.27M
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
205.58M
Revenue
$1
Gross profit
$1
Net income
-$19.57M
EBIT
-$19.57M
EBITDA
-$19.54M
Free cash flow
-$17.24M
Per share
Balance sheet
Liquidity
EPS
-$2.68
EPS diluted
-$2.68
Free cash flow per share
-$1.94
Book value per share
-$0.07
Revenue per share
$0
TBVPS
$0.49
Total assets
$4.38M
Total liabilities
$4.91M
Debt
$216,872
Equity
-$530,591
Working capital
-$717,363
Debt to equity
-0.41
Current ratio
0.85
Quick ratio
0.66
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-1.95B%
Gross margin
100%
Net margin
-1.96B%
Operating margin
-2.01B%
Return on assets
-201.8%
Return on equity
-350.6%
Return on invested capital
-903.7%
Return on capital employed
N/A
Return on sales
-1.96B%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKT stock price
How has the Inhibikase Therapeutics stock price performed over time
Intraday
3.72%
1 week
-2.85%
1 month
30.08%
1 year
149.59%
YTD
141.73%
QTD
136.15%
Financial performance
How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$1
Gross profit
$1
Operating income
-$20.06M
Net income
-$19.57M
Gross margin
100%
Net margin
-1.96B%
Inhibikase Therapeutics's gross profit has plunged by 100% YoY and by 100% from the previous quarter
The revenue has plunged by 100% YoY and by 100% from the previous quarter
Inhibikase Therapeutics's net income has decreased by 6% from the previous quarter and by 2.3% YoY
Inhibikase Therapeutics's operating income has decreased by 6% from the previous quarter
Growth
What is Inhibikase Therapeutics's growth rate over time
Valuation
What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
27.27M
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
205.58M
The EPS has grown by 27% YoY and by 3.6% from the previous quarter
The equity has dropped by 110% since the previous quarter and by 104% year-on-year
The revenue has plunged by 100% YoY and by 100% from the previous quarter
Efficiency
How efficient is Inhibikase Therapeutics business performance
The return on assets has dropped by 146% year-on-year and by 44% since the previous quarter
IKT's return on equity has dropped by 81% since the previous quarter
IKT's return on invested capital is down by 28% since the previous quarter
Dividends
What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKT.
Financial health
How did Inhibikase Therapeutics financials performed over time
The total assets is 11% smaller than the total liabilities
IKT's quick ratio has dropped by 89% year-on-year and by 69% since the previous quarter
Inhibikase Therapeutics's current ratio has shrunk by 87% YoY and by 63% QoQ
The company's debt is 141% higher than its equity
The equity has dropped by 110% since the previous quarter and by 104% year-on-year
The company's debt fell by 39% QoQ and by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.